We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
- Authors
Ramanathan, Ramesh K.; Belani, Chandra P.; Singh, Deepti A.; Tanaka, Michael; Lenz, Heinz-Josef; Yun Yen; Kindler, Hedy L.; Iqbal, Syma; Longmate, Jeff; Mack, Philip C.; Lurje, Georg; Gandour-Edwards, Regina; Dancey, Janet; Gandara, David R.
- Abstract
To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC). Lapatinib was dosed at 1,500 mg/day orally continuously. Fifty-seven patients were accrued (BTC 17, HCC 40). Therapy was well tolerated. The response in BTC was 0% and in HCC was 5%. The progression free survival (PFS) for BTC and HCC patients was 1.8 (95% CI: 1.7–5.2) months and 2.3 (95% CI: 1.7–5.6) months. The median survival for BTC and HCC patients was 5.2 (95% CI 3.3–∞) months and 6.2 (95% CI: 5.1–∞) months. EGFR genotyping indicated HCC patients with <20 repeats have the lowest PFS. The occurrence of any skin rash significantly prolonged PFS and survival. Lapatinib was well-tolerated. There was evidence of activity in HCC, but therapy with lapatinib did not meet the predefined efficacy rate.
- Subjects
RESEARCH; DRUGS; BILIARY tract cancer; LIVER cancer; THERAPEUTICS
- Publication
Cancer Chemotherapy & Pharmacology, 2009, Vol 64, Issue 4, p777
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-009-0927-7